VBL says data shows MOSPD2 can play major role in breast cancer cell migration
VBL Therapeutics announced the publication of data on the potential role of MOSPD2 in metastatic breast cancer in the International Journal of Cancer. VBL's data demonstrate for the first time that MOSPD2 can play a major role in breast cancer cell migration and metastasis, and that targeting MOSPD2 may be employed to prevent the spreading of breast cancer cells. Histological analysis of specimens shows that MOSPD2 levels were correlated with the stage of tumor invasiveness, and were profoundly elevated in invasive and metastatic breast cancer, making it an attractive target for potential treatment of late-stage breast cancer. At the American Association of Cancer Research conference in April this year, VBL presented a late-breaking proof-of-concept study demonstrating antibody-mediated killing of MOSPD2-expressing cancer cells. VBL research has also shown that knocking-out the MOSPD2 gene in mice could protect the animals from developing some inflammatory diseases. The Company has generated antibodies that block immune cell migration and show efficacy in a model of multiple sclerosis. VBL is developing the VB-600 platform of biologic drug candidates for oncology and inflammatory indications. The Company plans to file an IND in this program by year-end 2019.